The Overheard at Frequency podcast explores issues surrounding hearing loss and the unmet needs of the patient community. Hosted by Colleen Chapman, Senior Director of Patient Advocacy and Government Affairs at Frequency Therapeutics, the podcast brings timely and interesting stories about hearing science, advocacy and innovation to our listeners.

In part 2 of this two-part episode, Colleen sits down with Carl LeBel, PhD, Frequency’s Chief Development Officer, to discuss news from Frequency’s Research & Development Event on November 9th, 2021, including pooled data from FX-322 studies and a new hearing restoration candidate, FX-345.

Those interested in watching Frequency’s R&D Event may do so at this link: https://investors.frequencytx.com/2021_Virtual_R-D_Event